266 Chapter 8 REFERENCES 1. Drigan RS, A.; Gelber, R. D.: Behavioral effects of corticosteroids in children with acute lymphoblastic leukemia. Med Pediatr Oncol 20:13-21, 1992 2. Felder-Puig RS, C.; Baumgartner, M.; Ortner, M.; Aschenbrenner, C.; Bieglmayer, C.; Voigtlander, T.; Panzer-Grumayer, E. R.; Tissing, W. J.; Koper, J. W.; Steinberger, K.; Nasel, C.; Gadner, H.; Topf, R.; Dworzak, M.: Glucocorticoids in the treatment of children with acute lymphoblastic leukemia and hodgkin’s disease: a pilot study on the adverse psychological reactions and possible associations with neurobiological, endocrine, and genetic markers. Clin Cancer Res 13:7093-100, 2007 3. Pound CMC, C.; Ni, A.; Athale, U.; Lewis, V.; Halton, J. M.: Corticosteroids, behavior, and quality of life in children treated for acute lymphoblastic leukemia; a multicentered trial. J Pediatr Hematol Oncol 34:517-23, 2012 4. van Hulst AM, Peersmann SHM, van den Akker ELT, et al: Risk factors for steroid-induced adverse psychological reactions and sleep problems in pediatric acute lymphoblastic leukemia: A systematic review. Psychooncology 30:1009-1028, 2021 5. Warris LT, van den Heuvel-Eibrink MM, Aarsen FK, et al: Hydrocortisone as an Intervention for Dexamethasone-Induced Adverse Effects in Pediatric Patients With Acute Lymphoblastic Leukemia: Results of a Double-Blind, Randomized Controlled Trial. J Clin Oncol 34:2287-93, 2016 6. Maurice-Stam H, Haverman L, Splinter A, et al: Dutch norms for the Strengths and Difficulties Questionnaire (SDQ) - parent form for children aged 2-18 years. Health Qual Life Outcomes 16:123, 2018 7. Hough R, Rowntree C, Goulden N, et al: Efficacy and toxicity of a paediatric protocol in teenagers and young adults with Philadelphia chromosome negative acute lymphoblastic leukaemia: results from UKALL 2003. Br J Haematol 172:439-51, 2016 8. Samardakiewicz MM-L, M.; Kowalczyk, J. R.: Corticosteroids-induced neuropsychiatric episodes in acute lymphoblastic leukemia adolescent patients. Psycho-Oncology 22:124-362, 2013 9. Elsman EBM, Flens G, de Beurs E, et al: Towards standardization of measuring anxiety and depression: Differential item functioning for language and Dutch reference values of PROMIS item banks. PLoS One 17:e0273287, 2022 10. Cella D, Yount S, Rothrock N, et al: The Patient-Reported Outcomes Measurement Information System (PROMIS): progress of an NIH Roadmap cooperative group during its first two years. Med Care 45:S3-S11, 2007 11. Oude Voshaar M, Terwee CB, Haverman L, et al: Development of a standard set of PROs and generic PROMs for Dutch medical specialist care : Recommendations from the Outcome-Based Healthcare Program Working Group Generic PROMs. Qual Life Res, 2023 12. Freyer DR, Lin L, Mack JW, et al: Lack of Concordance in Symptomatic Adverse Event Reporting by Children, Clinicians, and Caregivers: Implications for Cancer Clinical Trials. J Clin Oncol 40:1623-1634, 2022 13. Daniel LCL, Y.; Kloss, J. D.; Reilly, A. F.; Barakat, L. P.: The impact of dexamethasone and prednisone on sleep in children with acute lymphoblastic leukemia. Support Care Cancer 24:3897-906, 2016 14. Zupanec SJ, H.; Stremler, R.: Sleep habits and fatigue of children receiving maintenance chemotherapy for ALL and their parents. J Pediatr Oncol Nurs 27:217-28, 2010 15. Strazisar BG: Sleep Measurement in Children-Are We on the Right Track? Sleep Med Clin 16:649660, 2021
RkJQdWJsaXNoZXIy MTk4NDMw